OMER News and Press, Omeros Corporation From 06/06/22

The addiction treatment space has been pummeled along with everything else in the growth side of the stock market so far in 2022. For long-term investors, this could represent a huge gift, especially as some of the stocks in this space are also working in new domains and technologies, includi...

Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty. Omeros' decision to battle the FDA over its narsoplimab in treatment of HSCT-TMA is a good call, however, it speaks to rough tim...

Omeros (NASDAQ:OMER +7.9%) stock rose after the company posted better than-expected Q1 earnings, helped by royalties from ophthalmic product Omidria. Net loss for the quarter was $33M or $0.53 per share (beats by $0.08), compared to a net loss of $35.1M, or $0.57 per share, a year earlie...

Omeros Corporation (OMER) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitake...

Omeros press release (NASDAQ:OMER): Q1 GAAP EPS of -$0.53 beats by $0.08. Omeros earned royalties of $13.8M based on Rayner’s net sales of $27.7M, all of which were in the U.S., a $6.6M increase from the $21.1M of OMIDRIA net sales reported by Omeros in the prior year quarter...

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicatio...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. East...

Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting. Omeros' growing short interest and its sinking share price will likely continue until it provides posit...

Citing up to date short interest data as of Apr. 26, Cantor Fitgerald points out that the oncology-focused biopharmaceutical company Veru (NASDAQ:VERU) had the biggest jump in short interest under its coverage with a ~279% increase. Miami, Florida-based Veru (VERU) added more than 25% of valu...

Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an o...